当前位置： SCI文献检索 > JOURNAL OF HEPATOLOGY期刊下所有文献 > Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma.

Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma.

Abstract：

BACKGROUND AND AIMS:Little is known about EBV-associated intrahepatic cholangiocarcinoma (EBVaICC) due to its rarity. We aimed to comprehensively investigate the clinicopathology, tumor immune microenvironment (TIME) and genomic landscape of this entity in southern China. METHODS:We evaluated 303 ICCs using in situ hybridization for EBV, we compared clinicopathological parameters between EBVaICC and nonEBVaICC, and we analyzed EBV infection status, tumor-infiltrating lymphocytes (TILs) and genomic features of EBVaICC by immunohistochemistry, double staining, nested PCR, multiplex immunofluorescence staining, fluorescence in situ hybridization and whole exome sequencing. RESULTS:EBVaICC accounted for 6.6% of ICCs, with EBV latency type I infection and clonal EBV isolates form. Distinctive clinicopathological characteristics of EBVaICC included female predominance, younger patient predominance, solitary tumor, higher HBV infection rate, lower cirrhotic background and increased lymphoepithelioma-like (LEL) subtype proportion. EBVaICC had a significantly larger TIME component than nonEBVaICC. The LEL subtype of EBVaICC, which had a significantly increased density and proportion of CD20+ B cells and CD8+ T cells, was significantly related to longer 2-year OS and RFS than EBVaICC conventional type and nonEBVaICC. Both PD-1 and PD-L1 in TILs and PD-L1 in tumor cells were overexpressed in EBVaICC. Tumor microenvironment immune type (TMIT) I (PDL1-Tumor+/CD8-High) was significantly more common in EBVaICC than in nonEBVaICC. Mutated genes in at least three cases, including MUC4, DNAH1, GLI2, LIPE, MYH7, RP11-766F14.2 and WDR36, were uncovered. EBVaICC had different mutational pattern compared with reported liver fluke-associated cholangiocarcinoma and HBV-associated ICC. CONCLUSIONS:EBVaICC, as a subset of ICC, has unique etiological characteristics, clinicopathology and molecular genetics with a significantly larger TIME component. Most cases belong to TMIT I. Paradoxically, patients with EBVaICC could be candidates for immune checkpoint therapy.

journal_name

J Hepatol

journal_title

Journal of hepatology

authors

Huang YH,Zhang CZ,Huang QS,Yeong J,Wang F,Yang X,He YF,Zhang XL,Zhang H,Chen SL,Zheng YL,Deng R,Lin CS,Yang MM,Li Y,Jiang C,Kin-Wah Lee T,Ma S,Zeng MS,Yun JP

doi

10.1016/j.jhep.2020.10.037

subject

Has Abstract

pub_date

2020-11-16 00:00:00

eissn

0168-8278

issn

1600-0641

pii

S0168-8278(20)33763-6

pub_type

杂志文章

在线工具

Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma.